Exelixis should be bought on dip caused by ‘776 patent worries, says Truist

Truist analyst Asthika Goonewardene said a previous expert call anticipated Exelixis will lose the ‘776 polymorph patent, but thought that the company should win in their second wave of IP defense for its ‘439 and ‘440 patents, which should preserve Cabometyx intellectual property to 2030. In that context, Goonewardene encourages investors to buy the stock amid a dip that follows a Seeking Alpha article citing trader comments that the judge in Exelixis’ case with MSN Pharma “telegraphed” a ruling in favor of MSN on the ‘776 patent. The article coincides with Exelixis’ move lower today and the analyst adds that this “telegraph” comment is “getting airplay in investor/trader chat rooms,” while noting that closing arguments are scheduled for 2 pm today and that a verdict for this trial is expected in about November. Goonewardene has a Buy rating and $35 price target on Exelixis shares, which are down $2.14, or 11%, to $17.35 in afternoon trading.

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire